实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (4): 500-503.doi: 10.3969/j.issn.1672-5069.2023.04.012

• 非酒精性脂肪性肝病 • 上一篇    下一篇

非酒精性脂肪性肝病合并2型糖尿病患者血清瘦素、视黄醇结合蛋白4和胆碱酯酶水平变化及其临床意义研究*

尹会芬, 于红艳, 刘志平   

  1. 430000 武汉市汉口医院消化内科(尹会芬,刘志平);哈尔滨医科大学附属第一医院微创胆道外科(于红艳)
  • 收稿日期:2022-07-20 出版日期:2023-07-10 发布日期:2023-07-21
  • 通讯作者: 刘志平,E-mail:xiao655@sina.com
  • 作者简介:尹会芬,女,35岁,医学硕士,主治医师。E-mail:13419611445@163.com
  • 基金资助:
    *武汉市科技局医学科研项目(编号:WX20A08)

Changes of serum leptin, retinol-binding protein-4 and cholinesterase levels in patients with NAFLD and T2DM

Yin Huifen, Yu Hongyan, Liu Zhiping   

  1. Department of Gastroenterology, Hankou Hospital, Wuhan 430000,Hubei Province, China
  • Received:2022-07-20 Online:2023-07-10 Published:2023-07-21

摘要: 目的 探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者血清瘦素、视黄醇结合蛋白-4(RBP-4)和胆碱酯酶(ChE)水平变化及其临床意义。 方法 2019年4月~2022年4月我院诊治的NAFLD合并T2DM者74例(其中脂肪变轻度28例,中度25例,重度21例)、NAFLD患者30例、T2DM患者30例和健康人30例,采用ELISA法检测血清瘦素和RBP4,常规检测血清ChE水平,应用受试者工作特征曲线下面积(AUC)评估各指标预测重度肝脂肪变的效能。 结果 NAFLD合并T2DM患者胰岛素抵抗指数为(5.8±1.7),显著高于T2DM患者的(3.9±1.1)、NAFLD患者的(3.6±0.9)或健康人的【(1.9±0.4),P<0.05],而胰岛素敏感性指数为(-4.4±0.5),显著低于T2DM患者的(-4.0±0.4)、NAFLD患者的(-4.0±0.3)或健康人的【(-3.5±0.3),P<0.05];NAFLD合并T2DM患者血清瘦素和RBP4水平分别为(17.1±3.1)μg/L和(30.6±2.8)mg/L,显著高于T2DM患者【分别为(12.3±2.7)μg/L和(24.1±2.3)mg/L,P<0.05]或NAFLD患者【分别为(13.1±2.4)μg/L和(23.9±2.7)mg/L,P<0.05]或健康人【分别为(9.7±1.9)μg/L和(20.1±1.9)mg/L,P<0.05],而血清ChE水平为(8337.3±755.9)IU/L,显著低于T2DM患者【(9080.2±684.7)IU/L,P<0.05]或NAFLD患者【(9159.9±812.2)IU/L,P<0.05]或健康人【(9987.4±975.4)IU/L,P<0.05];重度脂肪变患者血清瘦素和RBP4水平显著高于中度或轻度患者,而血清ChE水平显著低于中度或轻度患者(P<0.05);应用血清瘦素、RBP4和ChE水平联合检测预测重度NAFLD的AUC为0.834,其灵敏度、特异度和准确度分别为76.2%、81.1%和79.7%,显著高于三项指标单独评估(其AUCs分别为0.727、0.739和0.708,P<0.05)。 结论 NAFLD合并T2DM患者血清瘦素和RBP4水平升高,而血清ChE水平降低,它们血清水平的变化可在一定程度上反映NAFLD的严重程度,联合检测可以帮助评估病情。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 胰岛素抵抗, 瘦素, 视黄醇结合蛋白-4, 胆碱酯酶

Abstract: Objective This study was aimed at exploring the implication of serum leptin, retinol binding protein-4 (RBP4) and cholinesterase (ChE) levels in patients with non-alcoholic fatty liver diseases (NAFLD) and type 2 diabetes mellitus (T2DM). Methods 74 patients with NAFLD and T2DM , including mild fatty liver in 28 cases, moderate in 25 cases and severe in 21 cases, 30 patients with NAFLD, 30 patients with T2DM and 30 healthy individuals were recruited in our hospital between April 2019 and April 2022. Serum leptin and RBP4 levels were detected by ELISA, and serum ChE level was detected routinely. The diagnostic performance was evaluated by the area under the receiver operating characteristic (AUC) curves. Results The HOMA-IR in patients with NAFLD and T2DM was(5.8±1.7), much higher than (3.9±1.1) in patients with T2DM, or (3.6±0.9) in patients with NAFLD or [(1.9±0.4), P<0.05] in healthy persons, while the insulin sensitivity index was(-4.4±0.5), much lower than(-4.0±0.4) in patients with T2DM or (-4.0±0.3) in patients with NAFLD or healthy persons [(-3.5±0.3), P<0.05]; serum leptin and RBP4 levels in patients with NAFLD and T2DM were (17.1±3.1)μg/L and (30.6±2.8)mg/L, significantly higher than [(12.3±2.7)μg/L and (24.1±2.3)mg/L, P<0.05] in patients with T2DM or [(13.1±2.4)μg/L and (23.9±2.7)mg/L, P<0.05] in patients with NAFLD or [(9.7±1.9)μg/L and (20.1±1.9)mg/L, P<0.05] in healthy persons, while serum ChE level was (8337.3±755.9)IU/L, much lower than [(9080.2±684.7)IU/L, P<0.05] in patients with T2DM or [(9159.9±812.2)IU/L, P<0.05] in patients with NAFLD or [(9987.4±975.4)IU/L, P<0.05] in healthy persons; serum leptin and RBP4 levels in NAFLD/T2DM patients with severe hepatic steatosis was much higher than, while serum ChE level was much lower than in those with moderate or mild hepatic steatosis(P<0.05); the AUC was 0.834, with the sensitivity, specificity and accuracy of 76.2%, 81.1% and 79.7% when serum leptin, RBP4 and ChE level combination was applied to predict severe hepatic steatosis in patients with NAFLD and T2DM, much superior to the three parameters alone evaluation ( with AUCs of 0.727, 0.739 and 0.708, respectively, P<0.05). Conclusion Serum leptin and RBP4 levels increase, while serum ChE level decrease, in patients with NAFLD and T2DM, which might be correlated to hepatic steatosis severity, and help evaluate the disease progression.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Insulin resistance, Leptin, Retinol-binding protein 4, Cholinesterase